ABSTRACT

Teriflunomide is a drug with immunosuppressive and selective immunomodulatory action, characterized by anti-inflammatory and antiproliferative properties. Several clinical studies have demonstrated the efficacy and safety of this drug in Multiple Sclerosis, estimating a significant improvement in cognitive performance.

The aim of our study is to evaluate the effects of teriflunomide by analysing the correlation between brain atrophy and the general cognitive profile and evaluating long-term changes. The effect of teriflunomide was studied in 30 patients with multiple sclerosis and 30 control subjects. Patients underwent a full cognitive profile assessment using the Brief Repeatable Battery of Neuropsychological Tests and a neuroimaging examination with a 3.0 T working scanner.

Our results suggested that treatment with teriflunomide could potentially not only slow down the accumulation of microstructural tissue damage in Grey Matter and With Matter, but also better preserve the cognitive profile, particularly by highlighting the benefits in the memory domain. Thanks to drug therapy, brain volume in our patients has remained constant, leading to improvements in memory, indicating teriflunomide as a neuroprotective potential and further strengthening the evidence of a link between loss of brain volume and cognitive impairment.

摘要

特立氟胺是一种具有免疫抑制和选择性免疫调节作用的药物，具有抗炎和抗增殖特性。几项临床研究已经证明了这种药物在多发性硬化症中的有效性和安全性，估计认知能力有显着改善。

我们研究的目的是通过分析脑萎缩与一般认知特征之间的相关性并评估长期变化来评估特立氟胺的效果。在 30 名多发性硬化症患者和 30 名对照受试者中研究了特立氟胺的作用。使用简要可重复的神经心理学测试电池组和使用 3.0 T 工作扫描仪的神经影像学检查对患者进行了全面的认知概况评估。

我们的研究结果表明，使用特立氟胺治疗可能不仅可以减缓灰质和 With Matter 中微结构组织损伤的累积，还可以更好地保持认知特征，特别是通过突出记忆领域的益处。由于药物治疗，我们患者的脑容量保持不变，从而改善了记忆力，表明特立氟胺具有神经保护潜力，并进一步加强了脑容量减少与认知障碍之间联系的证据。